PIN26 Lifetime Cost Estimation of Human Papillomavirus Related Diseases in China: a Modelling Study Using Real-World Data
W. Ding,Y. Ma,C. Ma,A. Ma,W. Tang
DOI: https://doi.org/10.1016/j.jval.2021.04.585
IF: 5.156
2021-01-01
Value in Health
Abstract:To estimate the lifetime costs of patients with HPV-related diseases in China. Real-world data were identified, screened and extracted under qualified procedure from hospital database (2012-2019). Markov models with six to eight health states were constructed to estimate lifetime costs of patients who developed into long-term diseases after infection, including cervical cancer (CC), vaginal cancer (VaC), vulvar cancer (VC), penile cancer (PC), anal cancer (AC), oral cavity cancer (OcC), oropharynx cancer (OrC) and larynx cancer (LC) . Transition probabilities were from published literatures. For short-term diseases like genital warts (GW) and recurrent respiratory papillomatosis (RRP), the average annual treatment costs were calculated. Nationwide costs were then extrapolated. Monte Carlo simulations and one-way sensitive analysis were conducted to control for uncertainties. We used 2021 as the baseline year, and 5% as the discounting rate. The lifetime cost per capita for localized, regional and distant CC are $24,845.1 (95%CI: 18,793.2∼30,897.0), $20,011.7 (95% CI:14,456.46∼25,567.0) and $18,205.7 (95%CI: 10,604.1∼25,807.3), respectively. For localized, regional and distant VaC, the lifetime cost are $19,278.9 (95%CI: 14,962.2∼23,595.6), $17,815.8 (95%CI: 13,214.7∼22,416.9) and $17,210.4 (95%CI: 12,172.3 ∼22,248.6), respectively. The base-case lifetime cost per capita for localized, regional and distant VC/PC/AC/OcC/OrC/LC are $22,405.0, $2,904.7, $19,995.2/$36,443.6, $33,718.0, $32,447.0/ $46,771.3, $42,195.5, $40,276.0/$25,576.0, $26,604.9, $27,005.8/$50,246.5, $49,730.5, $42,283.8/$59,597.1, $26,898.1, and $25,749.7, respectively. The base-case lifetime cost per capita for GW and RRP are $265.7 and $2,309.4, respectively. The lifetime costs are higher as compared with the non-lifetime costs used in Chinese economic evaluations of HPV vaccinations and have similar regularity with costs found in international studies. Our study is the first of its kind to use real-world data in estimating the HPV-related economic burden, and could provide references for future economic evaluations of HPV vaccination strategies.